Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05556265) looked at a medicine called deucravacitinib in people with alopecia areata — a condition where the immune system attacks hair follicles, causing hair loss. A total of 94 participants took part in the first 24-week phase: 32 received deucravacitinib once a day (called QD), 31 received it twice a day (called BID), and 31 received a placebo (an inactive treatment). The trial's main measurement for hair loss used a tool called the SALT score, which runs from 0 to 100 — where a lower number means less hair loss on the scalp. The trial also tracked the number of participants who experienced medical events (called adverse events) during the study, as well as blood test results and heart trace (ECG) readings. The reported data shows that, after 24 weeks, the average SALT score change from the starting point was −5.8 points in the once-daily deucravacitinib group, +1.0 points in the twice-daily group, and −7.3 points in the placebo group. (A negative number means the score went down, i.e. less hair loss on the scale, compared to where each group started.) Regarding medical events during the first 24 weeks, the reported data shows that 25 out of 32 participants in the once-daily group, 28 out of 31 in the twice-daily group, and 20 out of 31 in the placebo group experienced at least one adverse event. Serious adverse events were reported in 1 participant in each of the two deucravacitinib groups and none in the placebo group. The reported data shows no participants in any group reached the most severe grades (Grade 3 or 4) for abnormal blood test results across either study period. A small number of notable heart trace readings were recorded — 2 participants in the twice-daily group and 1 in the placebo group during the first period — but further detail on what these represented was not reported in the data provided. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Alopecia Areata Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with alopecia areata (a condition causing patchy hair loss) for at least 6 months.
- Your current episode of hair loss on the scalp has been ongoing for at least 6 months.
- Your current episode of hair loss covering 50% or more of your scalp has lasted no longer than 8 years.
- Your hair loss has been stable, meaning there has been no significant natural regrowth (more than 10%) in the last 6 months.
- At least 50% of your scalp hair is currently lost, as measured by a standard scoring tool called the SALT score — people with complete scalp hair loss, with or without body hair loss, may also be included.
Who may not be able to join:
- You have a different type of alopecia areata called "diffuse-type," or another kind of hair loss condition (such as traction alopecia or scarring hair loss conditions) rather than the standard patchy form.
- You have another active skin condition affecting your scalp that could make it difficult for the study team to accurately measure your hair loss.
- You have extensive tattoos on your scalp that could make it difficult for the study team to accurately measure your hair loss.
- There are additional criteria not listed here that may also affect whether you can join (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period; Number of Participants With Treatment Emergent Adverse Events in Placebo-Controlled Period; Number of Participants With Treatment Emergent Adverse Events in Active Treatment Period; Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in Placebo-Controlled Period; Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Labora...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.